介绍INNODIA项目的波兰分部

Q3 Medicine

Pediatric Endocrinology, Diabetes and Metabolism Pub Date : 2023-03-01 DOI:10.5114/pedm.2023.125365

Paulina Pokrywka, H. Kaminska, P. Jarosz-Chobot

{"title":"介绍INNODIA项目的波兰分部","authors":"Paulina Pokrywka, H. Kaminska, P. Jarosz-Chobot","doi":"10.5114/pedm.2023.125365","DOIUrl":null,"url":null,"abstract":"Type 1 diabetes (T1D) is an autoimmune disease in which the beta cells of the pancreas that produce insulin are destroyed by T lymphocytes [1]. According to the World Health Organization, in 2019 alone, diabetes was the direct cause of 1.5 million deaths [2]. So far, the disease process is not fully understood, and a cure has not yet been developed, which is why diabetes is one of the priority diseases under research in the World Health Organization’s first and second programmes of Innovative Medicines Initiative (IMI1 and IMI2) [3]. Of the 13 projects funded by IMI until October 2019, only one was targeted to type 1 diabetes – INNODIA [3].","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"C-27 1","pages":"57 - 58"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Introduction to the Polish branch of the INNODIA program\",\"authors\":\"Paulina Pokrywka, H. Kaminska, P. Jarosz-Chobot\",\"doi\":\"10.5114/pedm.2023.125365\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Type 1 diabetes (T1D) is an autoimmune disease in which the beta cells of the pancreas that produce insulin are destroyed by T lymphocytes [1]. According to the World Health Organization, in 2019 alone, diabetes was the direct cause of 1.5 million deaths [2]. So far, the disease process is not fully understood, and a cure has not yet been developed, which is why diabetes is one of the priority diseases under research in the World Health Organization’s first and second programmes of Innovative Medicines Initiative (IMI1 and IMI2) [3]. Of the 13 projects funded by IMI until October 2019, only one was targeted to type 1 diabetes – INNODIA [3].\",\"PeriodicalId\":39165,\"journal\":{\"name\":\"Pediatric Endocrinology, Diabetes and Metabolism\",\"volume\":\"C-27 1\",\"pages\":\"57 - 58\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Endocrinology, Diabetes and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pedm.2023.125365\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pedm.2023.125365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

1型糖尿病(T1D)是胰腺中产生胰岛素的β细胞被T淋巴细胞破坏的一种自身免疫性疾病[1]。根据世界卫生组织的数据，仅在2019年，糖尿病就直接导致150万人死亡[2]。迄今为止，人们尚未完全了解该疾病的发病过程，也尚未开发出一种治疗方法，这就是为什么糖尿病是世界卫生组织创新药物倡议(IMI1和IMI2)第一和第二个规划中重点研究的疾病之一[3]。截至2019年10月，IMI资助的13个项目中，只有一个是针对1型糖尿病的——INNODIA[3]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Introduction to the Polish branch of the INNODIA program

Type 1 diabetes (T1D) is an autoimmune disease in which the beta cells of the pancreas that produce insulin are destroyed by T lymphocytes [1]. According to the World Health Organization, in 2019 alone, diabetes was the direct cause of 1.5 million deaths [2]. So far, the disease process is not fully understood, and a cure has not yet been developed, which is why diabetes is one of the priority diseases under research in the World Health Organization’s first and second programmes of Innovative Medicines Initiative (IMI1 and IMI2) [3]. Of the 13 projects funded by IMI until October 2019, only one was targeted to type 1 diabetes – INNODIA [3].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Endocrinology, Diabetes and Metabolism Medicine-Pediatrics, Perinatology and Child Health

CiteScore

2.00

自引率

0.00%

发文量